Skip to main content

Table 2 Patients who received neoadjuvant chemotherapy in each group

From: Intra-mammary lymph nodes, an overlooked breast cancer prognostic tool?

Variables

Benign IMLNs Received Neoadj CTH (N = 13)

Malignant IMLNs Received Neoadj CTH (N = 13)

P-value

Neoadjuvant chemotherapy

Yes

13 (31%)

13 (27.1%)

0.686C

No

29 (69%)

35 (72.9%)

 

AxLN response after neoadjuvant chemotherapy

N-A

6 (46.2%)

4 (30.8%)

0.199C

N-B

1 (7.7%)

0 (0.0%)

 

N-C

3 (23.1%)

1 (7.7%)

 

N-D

3 (23.1%)

8 (61.5%)

 

IMLN response after neoadjuvant chemotherapy

N-A

12 (92.3%)

0 (0%)

< 0.001C

N-B

1 (7.7%)

0 (0%)

 

N-D

0.(0%)

13 (100%)

 

Miller grade tumor

1

0 (0%)

3 (23.1%)

 

2

3 (23.1%)

7 (53.8%)

 

3

1 (7.7%)

0 (0%)

 

4

1 (7.7%)

1 (7.7%)

0.020C

5

8 (61.5%)

2 (15.4%)

 
  1. AUnpaired t test, BMann–Whitney, Cchi-square